Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.
Eligibility criteria
Qualifiers
Patients of legal age (age ≥ 18 years)
Subjects affiliated to or benefiting from a social security scheme
Free, written and informed consent signed by the participant and the investigator
Sampling at diagnosis for MDS patients (WHO 2016 criteria)
Disqualifiers
Patient transfused with red blood cells within 120 days prior to collection
Patients treated with haematopoietic growth factors (EPO, TPO, G-CSF) within 30 days prior to collection
Patients with conditions that affect systemic iron metabolism: hemochromatosis, Gaucher disease, ferroportin disease, porphyria cutanea tarda
Person under a legal protection measure (legal protection, guardianship or curatorship)
Trial design
Treatments tested in this trial
- Biological sampling
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov